Key result
Wearable-derived heart rate variability correlates positively with RVEF in incident PAH.
Why the study?
PAH can progress to right ventricular failure, and while HRV is associated with increased mortality across populations, its association with disease severity in PAH had not been examined.
Does noninvasively measured heart rate variability (HRV) correlate with right ventricular ejection fraction (RVEF) and disease severity on cardiac MRI in adults with incident pulmonary arterial hypertension over 6 months?
Cohort (n=20)
No
Does noninvasively measured heart rate variability (HRV) correlate with right ventricular ejection fraction (RVEF) and disease severity on cardiac MRI in adults with incident pulmonary arterial hypertension over 6 months?
Answers are grounded in this paper and cite their sources.
Noninvasively measured heart rate variability (SDNN) and heart rate captured via a wearable chest strap strongly correlate with cardiac MRI measures of right ventricular function and coupling in incident PAH patients, offering a potential noninvasive tool for remote risk monitoring.
Pulmonary arterial hypertension (PAH) is a disease that can eventually progress to right ventricular failure. Heart rate variability (HRV), including standard deviation of R‐to‐R intervals (SDNN), has been associated with increased mortality across different populations. The purpose of this study was to examine the association between HRV and disease severity in PAH. This was a prospective cohort study of adult incident PAH patients who underwent cardiac magnetic resonance imaging (CMR) at baseline and following 6 months. Study subjects recorded HRV using wearable chest actigraphy devices for at least 1 h every 2 weeks. The primary end point was correlation between HRV and right ventricular ejection fraction (RVEF) on CMR. Multivariable mixed effects regression models were used. A total of 20 subjects completed the study, predominantly female and White race, with severe PAH at the time of enrollment that improved significantly following 6 months of treatment. Linear relationships were observed between HRV (SDNN) and measures of PAH severity on CMR, including RVEF (SDNN coefficient 0.18, p = 0.006) and right ventricular‐pulmonary arterial coupling ratio (SDNN coefficient 0.008, p = 0.003). Comparable relationships were observed between heart rate captured using HRV device and these CMR measures (RVEF coefficient −0.37, p = 0.007; coupling ratio coefficient −0.013, p = 0.016). We conclude that noninvasively captured HRV (SDNN) and heart rate strongly correlate with PAH disease severity (right ventricular structure and function) on CMR, and may complement existing methods of risk assessment in PAH, particularly in high‐risk incident PAH.
No takes yet. Share an insight, caveat, or question.
Jose et al. (2025) conducted a cohort in Pulmonary arterial hypertension (n=20). Noninvasively measured heart rate variability (SDNN and RMSSD) captured via wearable chest actigraphy device was evaluated on Correlation between right ventricular ejection fraction (RVEF) on cardiac magnetic resonance imaging (CMR) and heart rate variability (SDNN) (Linear coefficient 0.18, p=0.006). Noninvasively captured heart rate variability (SDNN) significantly correlated with right ventricular ejection fraction on cardiac MRI (linear coefficient 0.18, p = 0.006) in incident PAH patients.
Synapse has enriched 10 related papers. Consider them for comparative context: